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a b s t r a c t 
Background: Current dosing strategies of CFTR modulators are based on serum pharmacokinetics, but
drug concentrations in target tissues such as airway epithelia are not known. Previous data suggest that
CFTR modulators may accumulate in airway epithelia, and serum pharmacokinetics may not accurately
predict effects of chronic treatment.
Methods: CF (F508del homozygous) primary human bronchial epithelial (HBE) cells grown at air-liquid
interface were treated for 14 days with ivacaftor plus lumacaftor or ivacaftor plus tezacaftor, followed by
a 14-day washout period. At various intervals during treatment and washout phases, drug concentrations
were measured via mass spectrometry, electrophysiological function was assessed in Ussing chambers,
and mature CFTR protein was quantified by Western blotting.
Results: During treatment, ivacaftor accumulated in CF-HBEs to a much greater extent than either
lumacaftor or tezacaftor and remained persistently elevated even after 14 days of washout. CFTR activ- 
ity peaked at 7 days of treatment but diminished with further ivacaftor accumulation, though remained
above baseline even after washout.
Conclusions: Intracellular accrual and persistence of CFTR modulators during and after chronic treatment
suggest complex pharmacokinetic and pharmacodynamic properties within airway epithelia that are not
predicted by serum pharmacokinetics. Direct measurement of drugs in target tissues may be needed to
optimize dosing strategies, and the persistence of CFTR modulators after treatment cessation has impli- 























The basic defect in cystic fibrosis (CF) reflects loss of function
f the cystic fibrosis transmembrane conductance regulator (CFTR),
 plasma membrane protein involved in chloride and bicarbon-
te transport across cellular membranes. A key therapeutic strat-
gy for CF focuses on CFTR modulators, drugs designed to improve
he function of abnormal CFTR. All currently approved CFTR mod-
lators include the potentiator compound ivacaftor (discovered as
X-770, [1] ), which improves the gating efficiency of CFTR. Thera-∗ Corresponding author at: Division of Pediatric Pulmonology, Department of Pe- 
iatrics, University of North Carolina School of Medicine, 450-D MacNider Hall,
ampus Box 7217, Chapel Hill, NC 27599-7217, USA.
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ors lumacaftor (discovered as VX-809, [2] ) or tezacaftor (discov-
red as VX-661), which improve folding and maturation of CFTR
earing the F508del mutation. Combinations of a potentiator and a
orrector improve CFTR function and clinical outcomes in patients
omozygous for the F508del mutation, and next-generation thera-
ies with novel correctors such as elexacaftor (discovered as VX-
45) in combination with the approved ivacaftor/tezacaftor ther-
py were even more efficacious in clinical trials [3–6] (Clinical-
rials.gov identifiers NCT03525548, NCT035254 4 4, NCT03460990,
nd NCT03447249). Several other companies are developing poten-
iators and correctors as well, including the novel amplifier com-
ounds such as PTI-428 (Proteostasis Therapeutics) [7] .
Because a lack of validated CF animal models precluded in
ivo pharmacodynamic studies, dosing of ivacaftor and other CFTRney et al., Accumulation and persistence of ivacaftor in airway 
oi.org/10.1016/j.jcf.2020.04.010 
Fig. 1. MS analysis of CFTR modulator intracellular concentrations during treatment and washout phases in CF-HBE (F508del/F508del) cells. Ivacaftor continually accrued
during the treatment period, and only moderately declined during the washout period. (A) Lumacaftor or Ivacaftor was measured in treated (Luma/Iva) or untreated (DMSO)
samples. Lumacaftor displayed minimal accrual over the treatment phase and was undetectable within 7 days of washout. (B) Tezacaftor or Ivacaftor was measured in treated
(Teza/Iva) or untreated (DMSO) samples. Tezacaftor also only accrued to a minimal extent during the treatment phase and diminished throughout the two-week washout
phase. Both tezacaftor and lumacaftor concentrations were rapidly eliminated from CF-HBEs within 1 day of beginning washout (day 15), while ivacaftor levels were still







































































modulators in clinical trials were based on other criteria includ-
ing pharmacodynamic effects within in vitro cell culture systems,
serum pharmacokinetic studies, and early dose ranging (Phase II)
studies. While these approaches resulted in clinically effective dos-
ing regimens, they did not account for the pharmacokinetic prop-
erties of these drugs within their primary target tissue, airway ep-
ithelia. Currently approved CFTR modulators are very hydropho-
bic and protein bound, and animal studies of ivacaftor have in-
dicated accumulation within the lung and other tissues [8] . Our
own studies [9] suggested that both ivacaftor and lumacaftor accu-
mulate within cultured airway epithelia resulting in instability and
turnover of CFTR at the cell surface. These findings suggest that the
pharmacokinetic properties of these drugs within target tissues,
and thus their optimal dosing, may vary substantially from serum
pharmacokinetics. Indeed, genotype-phenotype studies [10] sug-
gest that even the modest restoration of CFTR activity observed in
vitro with modulators should lead to far more clinical efficacy than
was observed in the clinical trials [11 , 12] . 
To better understand the pharmacokinetic properties of CFTR
modulators in their primary target tissues, we exposed primary
human bronchial epithelia (HBE) homozygous for the F508del CFTR
mutation to ivacaftor in combination with either lumacaftor or
tezacaftor, reflecting two of the currently approved therapeutics.
Intracellular drug concentrations were measured using an estab-
lished mass spectrometric method to determine whether and to
what extent these drugs accumulate within CF-HBE during pro-
longed drug exposure and washout phases. The impact of these
drugs on both mature CFTR expression and physiological activity
were assessed. 
2. Materials and methods
2.1. Cell culture 
Primary HBE cells from 3 different patients homozygous for
the F508del genetic mutation, prepared as described previously
[13] , were gifted by Dr. Scott H. Randell (Marsico Lung Institute,
The University of North Carolina at Chapel Hill, USA). The cells
were obtained under protocol #03-1396 approved by the Univer-
sity of North Carolina at Chapel Hill Biomedical Institutional Re-
view Board. Cells were expanded in BEGM (Lonza) and then cul-Please cite this article as: T.N. Guhr Lee, D.M. Cholon and N.L. Quin
epithelia with prolonged treatment, Journal of Cystic Fibrosis, https://dured at air-liquid interface with a plating density of 250,0 0 0 cells
n 12 mm Millicell inserts (Millipore) in a modified BEGM [14] un-
il differentiated. Cells were treated with a combination of ivacaftor
VX-770, Selleck Chemicals) + lumacaftor (VX-809, Selleck Chem-
cals) or ivacaftor + tezacaftor (VX-661, Selleck Chemicals) daily
ith fresh media and drug changes, and DMSO was used as a ve-
icle control. Ivacaftor was administered at a 1 μM concentration,
nd lumacaftor and tezacaftor were used at 3 μM concentrations.
xposure to drug or vehicle lasted for a period of 1 day, 7 days,
r 14 days. After a 14 day chronic exposure period to either of the
ual combination therapies, cells underwent a washout phase last-
ng either 1 day, 7 days, or 14 days (15, 21, and 28 days after initi-
tion of treatment). Cultures were functionally analyzed in Ussing
hambers, or lysed/processed and assayed for drug concentrations
nd CFTR protein levels. 
.2. Functional measurements of CFTR 
Change in short-circuit current ( I sc ) was measured from CF-
BE cultures in Ussing chambers as previously described [13 , 15 , 16]
n a bilateral Krebs bicarbonate-Ringers solution. Amiloride
100 μM, Sigma-Aldrich) was added to the apical bath to inhibit
he epithelial sodium channel ENaC. Bilateral addition of forskolin
10 μM, Sigma-Aldrich) followed to stimulate CFTR channel activ-
ty. CFTR inhibitor-172 (10 μM, Sigma-Aldrich) was then apically
ntroduced to inhibit CFTR. Transepithelial resistance ( •cm 2 ) was
easured to assess monolayer integrity. UTP (100 μM, GE Health-
are) response for Ca 2 + channel activity was assessed as an inter-
al control. 
.3. Mass spectrometric analysis of drugs 
Ivacaftor, lumacaftor, and tezacaftor were organically extracted
rom cell lysates using an equal volume of methyl tert-butyl ether
MTBE), with ivacaftor and lumacaftor concentrations measured via
iquid chromatography/tandem mass spectrometry (LC/MS-MS) as
reviously described [9 , 17] . Tezacaftor concentrations were mea-
ured in a similar manner, using selected reaction monitoring of
he transition of m/z 521.5 → 449.1 (collision energy 15 eV) in tan-
em mass spectrometry, which generated a single peak at run time
.7 min. DMSO-treated CF-HBE lysates were spiked with known
FTR modulator concentrations for reference. ney et al., Accumulation and persistence of ivacaftor in airway 
oi.org/10.1016/j.jcf.2020.04.010 
Table 1
CFTR Modulator Intracellular Concentration in HBE (F508del/F508del) Cells. Averages of ivacaftor, lumacaftor, and tezacaftor concentrations (μM) ±
standard error of the mean. p -values were calculated for each modulator in comparison to the corresponding DMSO vehicle control.
DMSO Iva (Luma/Iva) p -value Iva (Teza/Iva) p -value Luma (Luma/Iva) p -value Teza (Teza/Iva) p -value
1 0.00 ± 0.00 2.80 ± 0.49 0.0247 2.01 ± 0.34 0.0059 1.05 ± 0.27 0.0598 1.64 ± 0.11 < 0.0001
7 0.00 ± 0.00 8.98 ± 0.76 < 0.0001 10.86 ± 1.01 < 0.0001 1.47 ± 0.13 < 0.0001 2.95 ± 0.24 < 0.0001
14 0.00 ± 0.00 20.96 ± 3.35 0.0041 20.33 ± 2.40 0.0005 1.59 ± 0.11 < 0.0001 3.53 ± 0.51 0.0021
15 0.00 ± 0.00 23.30 ± 2.98 0.0009 24.81 ± 3.65 0.0024 0.36 ± 0.04 0.0006 1.84 ± 0.55 0.1268
21 0.00 ± 0.00 20.95 ± 2.90 0.0016 21.28 ± 2.53 0.0005 0.03 ± 0.01 0.2937 0.59 ± 0.17 0.1217
28 0.00 ± 0.00 18.36 ± 2.18 0.0005 18.55 ± 1.83 0.0001 0.01 ± 0.00 0.3995 0.12 ± 0.03 0.0781
Fig. 2. Ussing chamber measurements of CFTR activity in CF-HBEs (F508del/F508del) treated with CFTR modulators. (A) Forskolin peaks measured by short-circuit current
( I sc ) were elevated in both treatment arms (Teza/Iva, Luma/Iva) compared to vehicle (DSMO) control for the duration of both the treatment and washout phases. Forskolin
peaks reached maximum at day 7 of the treatment arms. (B) CFTRinh172 inhibition was accentuated in both treatment arms compared to vehicle (DMSO) control during
both treatment and washout phases. CFTRinh172 inhibition reached maximum at day 7 of the treatment arm. (C) Transepithelial resistance ( R t ) demonstrates that the cell
monolayer remained intact over the course of the treatment period, indicating no toxic effects of the drugs compared to the vehicle (DMSO) control group. ∗ , + indicate 



















t  .4. CFTR protein maturation by immunoprecipitation/ western blot 
Western blot analysis of endogenous CFTR protein was per-
ormed as described previously [9 , 18] . Briefly, whole-cell lysates of
ully differentiated CF-HBE cultures were prepared and then CFTR
as immunoprecipitated. Samples were separated on 4 to 20% gra-
ient SDS–polyacrylamide gel electrophoresis gels (Bio-Rad) and
hen transferred to nitrocellulose. Blots were probed with mouse
onoclonal anti-CFTR antibodies and then with IRDye 680–goat
nti-mouse immunoglobulin G (Molecular Probes). Anti-actin (Cell
ignaling) was used as a loading control. Protein bands were visu-
lized using a Sapphire Biomolecular Imager (Azure Biosystems). 
p  
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Data analysis was performed using GraphPad PRISM (version
.1) software. Statistical significance was calculated using the Stu-
ent’s t- test or ANOVA with alpha at p = 0.05. 
. Results
Primary HBEs homozygous for F508del CFTR mutation were cul-
ured at air-liquid interface as described [14] . Cells were exposed
o a combination of either ivacaftor plus lumacaftor or ivacaftor
lus tezacaftor with drug and media exchanges daily for a totalney et al., Accumulation and persistence of ivacaftor in airway 
oi.org/10.1016/j.jcf.2020.04.010 
Fig. 3. CFTR protein maturation in CF-HBE (F508del/F508del) cells during treatment and washout phases. (A) Mature CFTR protein (band C, ∗) and immature CFTR protein 
(band B, •) visualized by Western blot analysis of HBE cultures derived from 3 CF (F508del/F508del) patients. Numbers at the top of the lanes represent days since treatment 
start. Actin is shown as a loading control. (B) Mature C band quantification, normalized to DMSO-treated control cells, shows increased amounts of mature CFTR protein in
lumacaftor plus ivacaftor-treated cells and tezacaftor plus ivacaftor-treated cells during the treatment phase, which parallels CFTR function shown in Fig. 2 . (C) Quantification



























a  of 14 days, with cells recovered for drug concentration measures,
CFTR protein, and CFTR functional measures at 1, 7, and 14 days
of treatment. A parallel set of cultured CF-HBEs were exposed to
drug as above for 14 days, then drug was removed and cells were
recovered at 1, 7, and 14 days into the washout period. 
3.1. Intracellular CFTR modulator concentrations during treatment 
and washout phases 
In cells treated with ivacaftor plus lumacaftor, measured intra-
cellular ivacaftor concentrations increased continually during the
two-week treatment period, with concentrations at 14 days > 7-
fold higher than on day 1 ( Fig. 1 a, Table 1 , Iva (Luma/Iva)). In con-
trast, lumacaftor intracellular concentrations increased modestly,
with a 1.5-fold increase over the treatment period ( Fig. 1 a, Table 1 ,
Luma (Luma/Iva)). Similar findings were observed in the ivacaftor
plus tezacaftor-treated cells, with substantial increases in ivacaftorPlease cite this article as: T.N. Guhr Lee, D.M. Cholon and N.L. Quin
epithelia with prolonged treatment, Journal of Cystic Fibrosis, https://during treatment (10 fold; Fig. 1 b, Table 1 , Iva (Teza/Iva)) but much
ore modest increases in tezacaftor (2.15 fold; Fig. 1 b, Table 1 ,
eza (Teza/Iva)). During the washout period, both lumacaftor and
ezacaftor concentrations decreased significantly within one day of
ashout, and were nearly undetectable by the end of the washout
eriod ( Fig. 1 , Table 1 ). In contrast, in both treatment groups
vacaftor intracellular concentrations declined slowly during the
ashout phase and remained substantially above concentrations
n treatment day 1 even after two weeks of washout ( Fig. 1 ). No
easurable drug was observed in vehicle (DMSO)-treated control
ells. 
.2. Functional CFTR activity during treatment and washout phases 
To assess CFTR functional activity, we performed Ussing cham-
er measurements on CF-HBE during treatment (days 1, 7, and 14)



























































































































easured as changes in short-circuit currents ( I sc ), were elevated
elative to DMSO-treated controls throughout the treatment period
n both ivacaftor/lumacaftor- and ivacaftor/tezacaftor-treated cells
 Fig. 2 a). Interestingly, forskolin responses reached maximum peak
t treatment day 7, and were significantly lower at treatment day
4 relative to day 7 ( Fig. 2 a), similar to results observed in pre-
ious studies [9 , 19] . During the washout phase, peak forskolin re-
ponses declined but remained above baseline even after 14 days
f washout ( Fig. 2 a). 
The forskolin-induced currents observed in the treatment phase
ere effectively inhibited by CFTR inhibitor-172 (CFTRinh172), con-
istent with functionally active CFTR protein ( Fig. 2 b). As with
he forskolin responses, inhibition of CFTR channel activity peaked
t day 7 of treatment in both lumacaftor and tezacaftor dual
reated cells, but were reduced after 14 days of treatment ( Fig. 2 b).
FTRinh172 significantly inhibited forskolin-induced currents dur-
ng the washout phase, but not consistently at all time points.
ransepithelial resistance ( •cm 2 ) over the course of the 28-day
reatment period remained high and did not significantly differ
ver time or among treatment or control groups ( Fig. 2 c), consis-
ent with a lack of toxic effects. 
.3. CFTR protein maturation during treatment and washout phases 
CFTR immunoblots were generally consistent with functional
tudies, showing increases in the mature, complex glycosylated C
and throughout the treatment period in both treatment groups,
nd decreases during washout to a level consistent with the DMSO
ontrols ( Fig. 3 a and b). Actin staining as a loading control was
imilar at all time points ( Fig. 3 a and c). 
. Conclusions
The introduction of CFTR modulator therapies represents a sig-
ificant advancement in the treatment and management of CF.
vacaftor is a pillar of all currently approved regimens, including
he recently approved triple combination therapy, and understand-
ng its pharmacokinetic properties could have substantial thera-
eutic implications. We observe extensive accumulation and per-
istence of ivacaftor in CF-HBEs exposed to concentrations simi-
ar to those observed in serum. Our findings are consistent with
ther in vitro and animal model studies that show high ivacaftor
oncentrations in lung and tracheal tissues following oral adminis-
ration [8] , as well as a recent study that demonstrated epithelial
vacaftor accumulation in patients with CF on modulator therapy
20] .
Our findings have two important implications. First, they sug-
est the pharmacokinetic and pharmacodynamic properties of
FTR modulators in airway epithelia are complex and pose con-
iderable challenges to optimizing dosing strategies. In particular,
he propensity of ivacaftor to accumulate within airway epithe-
ia suggests the possibility that dosing regimens based on serum
harmacokinetics may not accurately predict its pharmacodynamic
ffects. For exam ple, it is possible that longer dosing intervals for
vacaftor may be sufficient to maintain pharmacologically relevant
oncentrations within airway epithelia, with the added benefit of
inimizing systemic side effects. The concentrations we used in
ur treatment media are of similar magnitude to the concentra-
ions that are reported in patient plasma. Furthermore, since iva-
aftor has been shown to destabilize corrected F508del CFTR [9 , 19]
s well as other non-gating mutations [21] , accumulation within
irway epithelia with frequent dosing may offset the positive im-
acts. While these effects, if present, do not prevent clinical bene-
t from CFTR modulator therapy with current dosing, they may be
imiting these agents’ potential. Please cite this article as: T.N. Guhr Lee, D.M. Cholon and N.L. Quin
epithelia with prolonged treatment, Journal of Cystic Fibrosis, https://dThe second implication relates to precision medicine. A sub-
tantial number of CFTR modulators are currently in preclinical or
linical trials, suggesting a future in which multiple potential ther-
pies are available for individual patients, most of whom will al-
eady be on modulator therapy. Testing of biological cells or tissues
rom individual patients could be used to tailor the most effective
rug combination. One attractive precision medicine approach is
o use organoids from epithelial cell biopsies, which can be uti-
ized without the need for expansion, reducing the turnaround
ime from weeks to days [22 , 23] . However, our data suggest that
his strategy must be used cautiously in patients already on modu-
ator therapy, since ivacaftor persists in epithelia much longer than
ts serum half-life would predict. 
The mechanisms that underlie the intracellular accumulation
f ivacaftor are not fully understood. Ivacaftor is a very lipophilic
rug, and lipophilicity is known to contribute to tissue accumu-
ation [24] . In contrast, lumacaftor [25] and tezacaftor [26] are
ess lipophilic, which may explain why they have less propensity
o accumulate with time. However, we cannot rule out the pos-
ibility that other mechanisms such as specific transporters con-
ribute to drug accumulation. We also cannot rule out the possi-
ility that ivacaftor accumulation was influenced by co-treatment
ith a CFTR corrector, since our study focused on treatments for
508del and therefore did not include an ivacaftor monotherapy
rm. Epithelial ivacaftor accumulation was observed with both iva-
aftor monotherapy and combination therapy in a small clinical
tudy [20] , but may not have had the same deleterious effects
ince the G551D CFTR mutation in these patients is resistant to
vacaftor-mediated destabilization [9] . 
While our findings raise concerns about the pharmacokinetics
f CFTR modulators, further investigation is needed to determine
f the effects we observed in vitro also occur in vivo . Ivacaftor
nd other CFTR modulators are highly hydrophobic and protein
ound, which may alter the effective concentrations to which air-
ay epithelia are exposed in vivo . However, a recent clinical study
20] suggested that ivacaftor concentrations are significantly higher
n nasal epithelia relative to serum in patients on CFTR modulator
herapy, consistent with our findings. Of note, our culture systems
o not effectively mimic systemic drug metabolism, which is pri-
arily based in the liver. Further study in animal models and/or
uman subjects will be needed to understand and optimize CFTR
odulator dosing. 
In summary, our data suggest that CFTR modulators, partic-
larly ivacaftor, accumulate substantially within airway epithelia
nd can persist for prolonged periods of time even in the absence
f drug exposure. These findings have important implications for
rug treatments and suggest that quantitation of concentrations of
FTR therapeutics in target tissues may be necessary to optimize
osing strategies. The persistence of ivacaftor will also need to be
ccounted for in personalized medicine strategies that test biopsy
amples from patients already on modulator therapy. 
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